Role of raloxifene in the management of postmenopausal osteoporosis of rheumatoid arthritis patients

European Pharmaceutical Journal Pub Date : 2023-09-30 DOI:10.2478/afpuc-2023-0003

M. Sahebary, M. Sarafraz, M. Salari, T. Asadi Sakhmarresi

{"title":"Role of raloxifene in the management of postmenopausal osteoporosis of rheumatoid arthritis patients","authors":"M. Sahebary, M. Sarafraz, M. Salari, T. Asadi Sakhmarresi","doi":"10.2478/afpuc-2023-0003","DOIUrl":null,"url":null,"abstract":"Abstract Objective Due to the severe side effects of long-term treatment using hormone replacement therapy, Raloxifene (RLX) is introduced with beneficial effects on rheumatoid arthritis (RA) for postmenopausal women. This review was conducted to collect data from the available literature on RLX for the management of postmenopausal women suffering from RA. Method All studies published up to 2019 were searched in four databases, including Google Scholar, PubMed, Scopus, and Medline. All articles were searched using several keywords, including “Raloxifene” or “Evista” in combination with “Rheumatoid Arthritis” or “Autoimmunity”. Finally, six studies were selected for the review analysis of this study. In all studies, 60 mg/day RLX was administered for postmenopausal subjects. The majority of the studies showed that the use of RLX was effective in postmenopausal women who underwent corticosteroid therapy. No severe complications were reported after RLX therapy in patients with RA. Result Based on the obtained results, RLX is a selective estrogen receptor modulator that its short-term anti-arthritic effects are proven in the treatment of postmenopausal osteoporosis. It was well tolerated without serious adverse events. Conclusion It seems that RLX is a promising treatment candidate in postmenopausal RA due to its anti-arthritic and anti-osteoporotic effects and based on the outcomes of experimental postmenopausal arthritis in animal and human studies.","PeriodicalId":12070,"journal":{"name":"European Pharmaceutical Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Pharmaceutical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/afpuc-2023-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract Objective Due to the severe side effects of long-term treatment using hormone replacement therapy, Raloxifene (RLX) is introduced with beneficial effects on rheumatoid arthritis (RA) for postmenopausal women. This review was conducted to collect data from the available literature on RLX for the management of postmenopausal women suffering from RA. Method All studies published up to 2019 were searched in four databases, including Google Scholar, PubMed, Scopus, and Medline. All articles were searched using several keywords, including “Raloxifene” or “Evista” in combination with “Rheumatoid Arthritis” or “Autoimmunity”. Finally, six studies were selected for the review analysis of this study. In all studies, 60 mg/day RLX was administered for postmenopausal subjects. The majority of the studies showed that the use of RLX was effective in postmenopausal women who underwent corticosteroid therapy. No severe complications were reported after RLX therapy in patients with RA. Result Based on the obtained results, RLX is a selective estrogen receptor modulator that its short-term anti-arthritic effects are proven in the treatment of postmenopausal osteoporosis. It was well tolerated without serious adverse events. Conclusion It seems that RLX is a promising treatment candidate in postmenopausal RA due to its anti-arthritic and anti-osteoporotic effects and based on the outcomes of experimental postmenopausal arthritis in animal and human studies.

查看原文本刊更多论文

雷洛昔芬在类风湿关节炎患者绝经后骨质疏松症治疗中的作用

摘要目的针对长期使用激素替代疗法治疗类风湿关节炎(RA)的严重副作用，推荐雷洛昔芬(Raloxifene, RLX)治疗绝经后女性类风湿关节炎(RA)。本综述收集了有关RLX治疗绝经后妇女类风湿性关节炎的文献资料。方法在Google Scholar、PubMed、Scopus和Medline 4个数据库中检索截至2019年发表的所有研究。使用几个关键词搜索所有文章，包括“雷洛昔芬”或“Evista”联合“类风湿关节炎”或“自身免疫”。最后，选取6项研究对本研究进行综述分析。在所有研究中，绝经后受试者服用60毫克/天的RLX。大多数研究表明，使用RLX对接受皮质类固醇治疗的绝经后妇女有效。RA患者经RLX治疗后未见严重并发症。结果RLX是一种选择性雌激素受体调节剂，其短期抗关节炎作用在治疗绝经后骨质疏松症中得到证实。耐受性良好，无严重不良反应。结论RLX具有抗关节炎和抗骨质疏松的作用，在绝经后关节炎的动物和人体实验研究中，RLX是一种很有前景的治疗绝经后RA的药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Pharmaceutical Journal Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

0.60

自引率

0.00%

发文量

期刊介绍： European Pharmaceutical Journal publishes only original articles not previously published and articles that are not being considered or have not been submitted for publication elsewhere. If parts of the results have been published as conference abstract or elsewhere, it should be stated in references. The ethical standards of the Helsinki-Tokio Declaration should be kept. This should be mentioned in the Methods of manuscript. Reviews are published only on request. Authors, whose submitted research work was performed with the support of a company, should indicate this in Conflict of Interest.